Recombinant
RabMAb

Recombinant Anti-Caveolin-1 antibody [E249] - Caveolae Marker (HRP) (ab193893)

Overview

  • Product name

    Anti-Caveolin-1 antibody [E249] - Caveolae Marker (HRP)
    See all Caveolin-1 primary antibodies
  • Description

    Rabbit monoclonal [E249] to Caveolin-1 - Caveolae Marker (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: IHC-P, WBmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Caveolin-1 aa 150 to the C-terminus.

  • Positive control

    • WB: A431 whole cell lysate. IHC-P: FFPE human lung tissue sections.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

Properties

Applications

Our Abpromise guarantee covers the use of ab193893 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB 1/5000. Detects a band of approximately 20 kDa (predicted molecular weight: 20 kDa).

Target

  • Function

    May act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity (By similarity). Involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Recruits CTNNB1 to caveolar membranes and may regulate CTNNB1-mediated signaling through the Wnt pathway.
  • Tissue specificity

    Expressed in muscle and lung, less so in liver, brain and kidney.
  • Involvement in disease

    Defects in CAV1 are the cause of congenital generalized lipodystrophy type 3 (CGL3) [MIM:612526]; also called Berardinelli-Seip congenital lipodystrophy type 3 (BSCL3). Congenital generalized lipodystrophies are autosomal recessive disorders characterized by a near absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes.
  • Sequence similarities

    Belongs to the caveolin family.
  • Post-translational
    modifications

    The initiator methionine for isoform Beta is removed during or just after translation. The new N-terminal amino acid is then N-acetylated.
  • Cellular localization

    Golgi apparatus membrane. Cell membrane. Membrane > caveola. Membrane raft. Colocalized with DPP4 in membrane rafts. Potential hairpin-like structure in the membrane. Membrane protein of caveolae.
  • Information by UniProt
  • Database links

  • Alternative names

    • BSCL3 antibody
    • CAV antibody
    • CAV1 antibody
    • CAV1_HUMAN antibody
    • caveolae protein, 22 kD antibody
    • caveolin 1 alpha isoform antibody
    • caveolin 1 beta isoform antibody
    • Caveolin 1 caveolae protein 22kDa antibody
    • Caveolin-1 antibody
    • Caveolin1 antibody
    • cell growth-inhibiting protein 32 antibody
    • CGL3 antibody
    • LCCNS antibody
    • MSTP085 antibody
    • OTTHUMP00000025031 antibody
    • PPH3 antibody
    • VIP 21 antibody
    • VIP21 antibody
    see all

Images

  • IHC image of Caveolin-1 staining in a section of formalin-fixed paraffin-embedded human normal lung*. The section was pre-treated using pressure cooker heat mediated antigen retrieval with sodium citrate buffer (pH6) for 30mins, and incubated overnight at +4°C with ab193893 at a working dilution of 1/500. DAB was used as the chromogen (ab103723), diluted 1/100 and incubated for 10min at room temperature. The section was counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

    *Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre

  • Anti-Caveolin-1 antibody [E249] - Caveolae Marker (HRP) (ab193893) at 1/5000 dilution + A431 (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 20 kDa
    Observed band size: 20 kDa
    Additional bands at: 17 kDa (possible isoform)


    Exposure time: 10 seconds


    This blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab193893 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab193893 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab193893.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up